NowPatient Review
Best for: Brand-name GLP-1 access without a compounded route
NowPatient is a US-UK telehealth platform offering brand-name GLP-1 weight management access including Mounjaro, Wegovy (injection and oral tablet), and Saxenda. Consultations are free and patients pay only the cost of the prescribed medication, which means out-of-pocket tracks brand list prices (~$1,000-$1,350/mo without insurance). HQ Austin, TX.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
NowPatient is a solid telehealth option with balanced features and pricing.
Score Breakdown
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Mounjaro (brand, cash-pay) | brand | $1069 |
| Wegovy injection (brand, cash-pay) | brand | $1349 |
| Wegovy oral tablet (brand, cash-pay) | brand | $1349 |
| Saxenda (brand, cash-pay) | brand | $1349 |
✓ Pros
- •Free telehealth consultation — patients only pay the medication cost
- •Brand-name Mounjaro, Wegovy injection, Wegovy oral tablet, and Saxenda all available
- •One of the few telehealth platforms offering Wegovy in both injection and oral pill form
- •No compounded options — every drug is FDA-approved brand
✗ Cons
- •Cash-pay pricing tracks full brand list price (~$1,000-$1,350/mo)
- •Does not offer compounded semaglutide or tirzepatide (generally the cheaper route)
- •State availability not disclosed publicly — determined during intake
- •Phone: 1-866-967-1977, HQ Austin TX
- •Does NOT offer Foundayo (orforglipron)
Ready to start with NowPatient?
Starting at $1069/month. See current pricing and start your free consultation.
Sources & methodology
Our NowPatient review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of April 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Alternatives to NowPatient
Alan Meds
Best for: budget-conscious shoppers
Editorial score · methodology
AmberHealth
Best for: budget-conscious shoppers
Editorial score · methodology
Amble
Best for: mainstream telehealth GLP-1 access
Editorial score · methodology
Frequently Asked Questions
Ready to start with NowPatient?
Starting at $1069/month. See current pricing and start your free consultation.